Regeneron Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Regeneron Pharmaceuticals Inc (REGN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Regeneron Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 16,896M vs 488,619M combined for its competitors (3.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+21.1% annualized vs trailing 12 months), vs accelerating (+7.1%) for its tracked peer group.
- Growth: Regeneron Pharmaceuticals Inc generated 36.3% revenue growth year over year in Q3 2026, vs 12.1% for its competitors combined.
- Profitability: Its 38.1% net margin compares with 15.3% for the peer group.
- Scale: Regeneron Pharmaceuticals Inc ranks #15 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 1.6% of industry market cap.
- Peer revenue share: Regeneron Pharmaceuticals Inc accounted for 3.8% of combined revenue among its tracked peer group, up from 3.1% a year earlier.
- Peer differentiation: Revenue per employee of $1.10M compares with $1.02M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
REGN Sales vs. its Competitors, Q3 2026
Regeneron Pharmaceuticals Inc reported revenue growth of 36.27 % year on year in Q3 2026, above its competitors' combined revenue growth of 12.13 %.
With a net margin of 38.09 %, Regeneron Pharmaceuticals Inc achieved higher profitability than its competitors (15.27 %).
Regeneron Pharmaceuticals Inc generated 3.76 % of the combined sales of its peer group, up from 3.12 % a year earlier.
API endpoints for this dataset
Regeneron Pharmaceuticals Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Regeneron Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Regeneron Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Regeneron Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (11) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Regeneron Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 36.3% for Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc's share of combined industry revenue moved from 0.78% to 0.98%, a gain of 0.20 percentage points.
Regeneron Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | Yes | Yes | Yes | No |
| Competitors combined (343) | ||||
| High-Confidence Competitors (42) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
REGN Stock Performance relative to its Competitors
REGN Stock Performance relative to High-Confidence Competitors
REGN Stock Performance relative to Similar-Size Competitors
REGN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Jasper Therapeutics Inc | 282.9% | Outperformed |
| 3 | Rockwell Medical inc | 282.9% | Outperformed |
| 4 | Gt Biopharma Inc | 282.9% | Outperformed |
| 5 | Adlai Nortye Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Regeneron Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Regeneron Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Regeneron Pharmaceuticals Inc |
95,438.47 | 16,896.20 |
 Eli Lilly And Company |
1,231,998.60 | 86,462.00 |
 Akari Therapeutics Plc |
883,207.78 | - |
 Johnson and Johnson |
682,057.53 | 99,335.00 |
 Beone Medicines Ltd |
623,340.26 | 6,128.24 |
 Abbvie Inc |
514,907.76 | 66,014.00 |
| SUBTOTAL | 6,956,390.90 | 912,114.99 |
Sign in to see all competitors of Regeneron Pharmaceuticals Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Regeneron Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Regeneron Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Regeneron Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Omniab Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Kodiak Sciences Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Nutra Pharma Corp | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Adverum Biotechnologies Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Zai Lab Limited | Company report | 85% |
| INVO | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Alimera Sciences Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Eyepoint Inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Unity Biotechnology Inc | Company report | 85% |
| Kalvista Pharmaceuticals Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Our Marketed Products | Company report | 85% |
| FENCF | Company report | 85% |
| Biocon Biologics Ltd | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Canton Strategic Holdings Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Fennec Pharmaceuticals Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Otonomy Inc | Company report | 85% |
| Ocular Therapeutix Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
| Apellis Pharmaceuticals Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Cymabay Therapeutics Inc | Company report | 85% |
| Karyopharm Therapeutics Inc | Company report | 85% |
| Argenx Se | Company report | 85% |
| Sanofi | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Neurogene Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Madrigal Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Rocket Pharmaceuticals Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
Company report basis, confidence, active dates and source counts for Regeneron Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Regeneron Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Regeneron Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 95,438 | 1,096,444 | 312,615 |
| Eli Lilly And Company | 1,231,999 | 1,729,240 | 551,594 |
| Akari Therapeutics Plc | 883,208 | - | -4,674,667 |
| Johnson and Johnson | 682,058 | 705,504 | 114,311 |
| Beone Medicines Ltd | 623,340 | 510,686 | 54,642 |
| Abbvie Inc | 514,908 | 1,158,140 | 181,509 |
| PEERS TOTAL | 6,860,952 | 1,017,933 | 115,788 |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Regeneron Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Regeneron Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Regeneron Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Regeneron Pharmaceuticals Inc ranks #15 of 495 companies by market capitalization in its industry, holding 1.63 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,232,412 | 20.92 % |
| 2 | Johnson and Johnson | 679,690 | 11.54 % |
| 3 | Beone Medicines Ltd | 623,340 | 10.58 % |
| 4 | Abbvie Inc | 514,617 | 8.74 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 15 | Regeneron Pharmaceuticals Inc | 95,800 | 1.63 % |
Market cap and industry share for the rest of Regeneron Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Regeneron Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 10 | Astrazeneca Plc | 146,266 | 12.95 % |
| 11 | Vertex Pharmaceuticals Inc | 138,089 | 29.99 % |
| 12 | Bristol myers Squibb Company | 127,662 | 33.68 % |
| 13 | Sanofi | 116,653 | -3.84 % |
| 14 | Gsk Plc | 1,234 | 12.3% |
| 15 | Regeneron Pharmaceuticals Inc | 95,800 | 39.71 % |
| 16 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
| 17 | Royalty Pharma Plc | 1,234 | 12.3% |
| 18 | Spyre Therapeutics Inc | 1,234 | 12.3% |
| 19 | Zoetis Inc | 1,234 | 12.3% |
| 20 | Takeda Pharmaceutical Company Limited | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Regeneron Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Regeneron Pharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 89.10 % | 37.99 % (avg) | +51.1 pp |
| Operating Margin | 28.79 % | industry median | +22.4 pp |
| EBITDA Margin | 37.90 % | -6.20 % (avg) | +44.1 pp |
| Capital Intensity (Capex / Revenue) | 6.04 % | 7.59 % (avg) | -1.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Regeneron Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 16.7x | 26.6x | -9.9x |
| EV / EBITDA | 12.3x | 15.9x | -3.6x |
| P/B | 2.5x | 4.3x | -1.8x |
| Return on Equity | 15.07 % | industry aggregate | -10.12 % |
| Return on Invested Capital | 7.05 % | -9.82 % (avg) | 16.87 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Regeneron Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 16.11 % | 15.33 % | 8.06 % | 89.14 % | -24.26 % | 7.76 % | 8.27 % | 0.99 % |
| Operating Margin | 38.08 % | 28.10 % | 42.09 % | 55.67 % | 38.93 % | 30.85 % | 28.10 % | 24.95 % |
| Return on Invested Capital | 15.39 % | 9.99 % | 15.06 % | 26.18 % | 10.53 % | 7.79 % | 6.62 % | 5.42 % |
| P/E | 16.4x | 19.6x | 16.8x | 8.8x | 19.2x | 23.7x | 22.0x | 16.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Regeneron Pharmaceuticals Inc's Strategic Group Map
Regeneron Pharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Regeneron Pharmaceuticals Inc's trailing-12-month revenue growth of 18.6% and operating margin of 28.8% compares with an average of 12.7% growth and 29.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Regeneron Pharmaceuticals Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Regeneron Pharmaceuticals Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Regeneron Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.08x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Regeneron Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 6.04 % vs industry average 7.59 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Regeneron Pharmaceuticals Inc's dedicated Suppliers and Customers pages, not here.
Regeneron Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Regeneron Pharmaceuticals Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Regeneron Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 22.4 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+21.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 10.1 points below the industry aggregate.
- Low relative market share vs the industry leader (0.08x).
Opportunities
- Trades at a lower P/E than the industry average (16.7x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (53.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Regeneron Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Regeneron Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| PEERS TOTAL | +11.0 % | +13.2 % |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Regeneron Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
Regeneron Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Regeneron Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Regeneron Pharmaceuticals Inc | 19.99 | 5.65 |
| Eli Lilly And Company | 44.77 | 14.25 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 42.14 | 6.87 |
| Beone Medicines Ltd | 941.09 | 101.72 |
| Abbvie Inc | 50.01 | 7.80 |
| PEERS AVERAGE | 65.23 | 7.63 |
Sign in to see all peers for Regeneron Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.